COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Releases

News Releases

Date
Title
Document
November 3, 2021
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
PDF Version
October 21, 2021
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
PDF Version
October 20, 2021
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
PDF Version
September 30, 2021
BioDelivery Sciences International to Host ELYXYB™ Investor Day
PDF Version
September 9, 2021
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
PDF Version
September 7, 2021
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference
PDF Version
September 3, 2021
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
PDF Version
August 4, 2021
BioDelivery Sciences Reports Second Quarter 2021 Results
PDF Version
August 4, 2021
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
PDF Version
July 22, 2021
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021
PDF Version

Investor Presentation

More information is coming soon.


Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
November 3, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.